This results, together with the expression of PGE2 receptors in KS [39], and the present identification of COX-2 activation as a key vGPCR oncogenic signaling component, further support the proposed role for COX-2 [34,37–39] as a therapeutic target in Kaposi’s Sarcoma. The gene discussed is PTGS2; the disease is Kaposi's sarcoma.